Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Net Income (2017 - 2025)

Lexaria Bioscience's Net Income history spans 9 years, with the latest figure at -$1.6 million for Q4 2025.

  • For Q4 2025, Net Income rose 41.45% year-over-year to -$1.6 million; the TTM value through Nov 2025 reached -$10.8 million, down 47.48%, while the annual FY2025 figure was -$11.9 million, 106.97% down from the prior year.
  • Net Income for Q4 2025 was -$1.6 million at Lexaria Bioscience, up from -$2.7 million in the prior quarter.
  • Across five years, Net Income topped out at -$25000.0 in Q1 2021 and bottomed at -$3.8 million in Q2 2025.
  • The 5-year median for Net Income is -$1.7 million (2022), against an average of -$1.8 million.
  • The largest annual shift saw Net Income tumbled 66882.73% in 2021 before it soared 49.53% in 2024.
  • A 5-year view of Net Income shows it stood at -$2.0 million in 2021, then rose by 15.38% to -$1.7 million in 2022, then skyrocketed by 33.24% to -$1.1 million in 2023, then plummeted by 137.73% to -$2.7 million in 2024, then surged by 41.45% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Net Income are -$1.6 million (Q4 2025), -$2.7 million (Q3 2025), and -$3.8 million (Q2 2025).